27.83
0.09 (0.32%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bullish |
| Biotechnology (Global) | Bearish | Bullish | |
| Stock | BridgeBio Pharma, Inc. | Bullish | Bullish |
Analyst Consensus
6 Buy
Avg. Price @ Call: 30.33
|
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| 52 Weeks Range |
12.75 - 44.32
|
|
| Price Target Range | ||
| High | 70.00 (Cantor Fitzgerald, 151.53%) | Buy |
| Median | 48.50 (74.27%) | |
| Low | 45.00 (JP Morgan, 61.70%) | Buy |
| Average | 51.83 (86.25%) | |
| Total | 6 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 14 May 2024 | 50.00 (79.66%) | Buy | 28.95 |
| JP Morgan | 20 Mar 2024 | 45.00 (61.70%) | Buy | 28.63 |
| Cantor Fitzgerald | 19 Mar 2024 | 70.00 (151.53%) | Buy | 28.43 |
| 11 Mar 2024 | 60.00 (115.59%) | Buy | 28.94 | |
| Mizuho | 05 Mar 2024 | 53.00 (90.44%) | Buy | 29.60 |
| HC Wainwright & Co. | 04 Mar 2024 | 47.00 (68.88%) | Buy | 32.36 |
| Citigroup | 23 Feb 2024 | 46.00 (65.29%) | Buy | 34.00 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |